Beacon Pharmaceuticals
Pharmaceutical company of Bangladesh
From Wikipedia, the free encyclopedia
Beacon Pharmaceuticals PLC is a Bangladeshi pharmaceutical company that develops generic version of medications.
| Company type | Public |
|---|---|
| DSE: BEACONPHAR, CSE: BEACONPHAR | |
| Industry | Pharmaceutics Biotechnology |
| Founded | 2006 |
| Headquarters | , Bangladesh |
Key people | Mohammad Ebadul Karim Bulbul, (MD) |
| Products | Sofosvel, Darvoni, Tagrix, Crizonix, Daclavir, Soforal, Afanix, Axinix, Brigaix, Baricinix, Cabozanix, Dasanix, Hernix, Elbonix, Ibrutix, Lenvanix, Palbonix, Regonix, Tofacinix, and Wedica |
| Revenue |  US$56 million (2019) |
 US$27 million (2019) | |
| US$4 million (2019) | |
| Total assets | US$100 million (2021 |
Number of employees | 4,000 (2021) |
| Website | beaconpharma |
Beacon manufactures more than 200 generic drugs and 65 oncology products. Beacon is the first company in Bangladesh to start export of cancer drugs.[1][2] The company is exporting its products to Asia, Africa, Europe and Latin America. Beacon is public limited company listed in Dhaka & Chittagong stock exchange. About 2000 people are working in this company.[3][4][5]
Beacon has introduced a number of global first generics.[6]
The company's commercially available products include velpatasvir/sofosbuvir, sofosbuvir/daclatasvir, osimertinib, crizotinib, daclatasvir, sofosbuvir, afatinib, axitinib, brigatinib, baricitinib, cabozantinib, dasatinib, neratinib, eltrombopag, ibrutinib, lenvatinib, palbociclib, regorafenib, tofacitinib, and trelagliptin.
BEACON Medicare Limited(BML)[7] is the exclusive global marketing & distribution partner of Beacon Pharmaceuticals Limited.